Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives

SIMPLE SUMMARY: Urothelial bladder cancer (BC) is one of the most fatal cancers, with a dismal five-year survival rate of 5% in patients with metastatic disease. Clinically relevant benefits of immunotherapy in advanced or metastatic bladder cancer have led to Food and Drug Administration (FDA) appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Roviello, Giandomenico, Catalano, Martina, Santi, Raffaella, Palmieri, Valeria Emma, Vannini, Gianmarco, Galli, Ilaria Camilla, Buttitta, Eleonora, Villari, Donata, Rossi, Virginia, Nesi, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431680/
https://www.ncbi.nlm.nih.gov/pubmed/34503220
http://dx.doi.org/10.3390/cancers13174411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431680/
https://www.ncbi.nlm.nih.gov/pubmed/34503220
http://dx.doi.org/10.3390/cancers13174411

Ejemplares similares